The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Addition of carfilzomib as a third agent in lenalidomide-refractory patients with multiple myeloma
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the benefit of adding carfilzomib as a third agent to lenalidomide-based doublet regimens in patients with multiple myeloma who are refractory to lenalidomide. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
